BPC-157
Purity: ≥98%
From $52.00
≥98%HPLC Purity
COAIncluded
USAShipped
Survodutide Peptide
Dual glucagon/GLP-1 receptor agonist peptide. Studied for dual incretin receptor co-activation and metabolic pathway research.
$95.00
Quick Facts
| SKU | ACR-SURVO |
|---|---|
| Sequence | Modified glucagon analog |
| Purity | ≥97% |
| Physical Form | Lyophilized Powder |
| Storage | Store at -20°C. |
What is Survodutide?
Survodutide (BI 456906) is a dual glucagon receptor (GCGR) and GLP-1 receptor (GLP-1R) agonist developed as an acylated peptide with optimized dual receptor co-agonism. It represents the emerging class of dual/multi-agonist incretin peptides.
The dual agonism strategy combines GLP-1R activation (promoting insulin secretion and satiety signaling) with GCGR activation (promoting hepatic lipid oxidation and energy expenditure). Published research has investigated the balanced receptor activation profile and downstream cAMP signaling.
For laboratory research use only.
Frequently Asked Questions
What is Survodutide?
Survodutide is a dual GLP-1/glucagon receptor agonist that co-activates both incretin pathways. GLP-1R activation promotes satiety signaling while GCGR activation promotes hepatic energy expenditure. For research use only.
For laboratory and research use only. Not intended for human or animal consumption. All product information is derived from published preclinical research and does not constitute medical advice or claims.